Login to Your Account



Biotech Fears Myriad Decision Could Be a Slippery Slope

By Mari Serebrov
Washington Editor

Thursday, April 11, 2013

Biotech Supreme Court watchers are looking at the what ifs ahead of Monday's arguments in a case that could overturn 30 years of established precedent, undoing isolated DNA claims and possibly threatening thousands of patents on proteins and other compounds that could be deemed "products of nature."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription